Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of Down syndrome

Prenatal Diagnosis

Volumn 30, Issue 5, 2010, Pages 471-477

  Huang, Tianhua ^a   Hoffman, Barry ^b   Meschino, Wendy ^a,c   Kingdom, John ^b   Okun, Nanette ^b  

^a NORTH YORK GENERAL HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adverse pregnancy outcomes; Alpha fetoprotein; Maternal serum pregnancy associated plasma protein A; Prenatal screening; Total human chorionic gonadotrophin; Unconjugated oestriol

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN; ESTRIOL; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADVERSE OUTCOME; ARTICLE; CANADA; CONTROLLED STUDY; DOWN SYNDROME; FALSE POSITIVE RESULT; FEMALE; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL SERUM; MEDICAL RECORD REVIEW; PREDICTION; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; SECOND TRIMESTER PREGNANCY;

ADULT; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN; DOWN SYNDROME; ESTRIOL; FALSE POSITIVE REACTIONS; FEMALE; FETAL DEATH; HUMANS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PREMATURE BIRTH; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 77951734507     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2505     Document Type: Article

References (36)

1. Chandra S, Scott H, Dodds L, Watts C, Blight C, Van Den Hof M. 2003. Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. Am J Obstet Gynecol 189: 775-781. (Pubitemid 37194104)
2. Chitayat D, Farrell SA, Huang T, Meier C, Wyatt PR, Summers AM. 2002. Double-positive maternal serum screening results for Down syndrome and open neural tube defects: An indicator for fetal structural or chromosomal abnormalities and adverse obstetric outcomes. Am J Obstet Gynecol 187: 758-763.
3. Cuckle H, Sehmi I, Jones R. 1998. Maternal serum inhibin A can predict preeclampsia. Br J Obstet Gynaecol 105: 1101-1103. (Pubitemid 28461504)
4. D'Anna R, Baviera G, Corrado F, Leonardi I, Buemi M, Jasonni VM. 2002. Is mid-trimester maternal serum inhibin-A a marker of preeclampsia or intrauterine growth restriction? Acta Obstet Gynecol Scand 81: 540-543. (Pubitemid 34628083)
5. Davidson EJ, Riley SC, Roberts SA, Shearing CH, Groome NP, Martin CW. 2003. Maternal serum activin, inhibin, human chorionic gonadotrophin and alpha-fetoprotein as second trimester predictors of preeclampsia. BJOG 110: 46-52.
6. Dugoff L, Cuckle HS, Hobbins JC, et al. 2008. Prediction of patient-specific risk for fetal loss using maternal characteristics and firstand second-trimester maternal serum Down syndrome markers. Am J Obstet Gynecol 199: 290.e1-290.e6.
7. Dugoff L, Hobbins JC, Malone FD, et al. 2004. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 191: 1446-1451. (Pubitemid 39421612)
8. Dugoff L, Hobbins JC, Malone FD, et al. 2005. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 106: 260-267. (Pubitemid 41023261)
9. Erez O, Romero R, Espinoza J, et al. 2008. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small- orgestational age. J Matern Fetal Neonatal Med 21: 279-287. (Pubitemid 351652513)
10. Goetzl L, Krantz D, Simpson JL, et al. 2004. Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss. Obstet Gynecol 104: 30-36. (Pubitemid 40458901)
11. Gonen R, Shahar R, Grimpel YI, et al. 2008. Placental protein 13 as an early marker for preeclampsia: a prospective longitudinal study. BJOG 115: 1465-1472.
12. Hamar BD, Buhimschi IA, Sfakianaki AK, et al. 2006. Serum and urine inhibin A but not free activin A are endocrine biomarkers of severe preeclampsia. Am J Obstet Gynecol 195: 1636-1645.
13. Huang T, Alberman E, Watt HC, Wald NJ. 2003. Using Down syndrome serum screening results to predict low birthweight. Prenat Diagn 23: 420-426. (Pubitemid 36596973)
14. Huang T, Owolabi T, Summers AM, Meier C, Wyatt PR. 2005. The identification of risk of spontaneous fetal loss through second-trimester maternal serum screening. Am J Obstet Gynecol 193: 395-403. (Pubitemid 41159533)
15. Kang JH, Farina A, Park JH, et al. 2008. Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: correlation with the week of onset and the severity. Prenat Diagn 28: 704-709.
16. Keelan JA, Taylor R, Schellenberg JC, Groome NP, Mitchell MD, North RA. 2002. Serum activin A, inhibin A, and follistatin concentrations in preeclampsia or small for gestational age pregnancies. Obstet Gynecol 99: 267-274. (Pubitemid 34114000)
17. Krantz D, Goetzl L, Simpson JL, et al. 2004. Association of extreme first-trimester free human chorionic gonadotropin-beta,pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 191: 1452-1458. (Pubitemid 39421613)
18. Lambert-Messerlian GM, Silver HM, Petraglia F, et al. 2000. Second-trimester levels of maternal serum human chorionic gonadotropin and inhibin a as predictors of preeclampsia in the third trimester of pregnancy. J Soc Gynecol Investig 7: 170-174. (Pubitemid 30349162)
19. Lepage N, Chitayat D, Kingdom J, Huang T. 2003. Association between second-trimester isolated high maternal serum maternal serum human chorionic gonadotropin levels and obstetric complications in singleton and twin pregnancies. Am J Obstet Gynecol 188: 1354-1359. (Pubitemid 36589135)
20. Leung TY, Chan LW, Leung TN, Fung TY, Sahota DS, Lau TK. 2006. First-rimester maternal serum levels of placental hormones are independent predictors of second-trimester fetal growth parameters. Ultrasound Obstet Gynecol 27: 156-161.
21. Milunsky A, Nebiolo L. 1996. Maternal serum triple analyte screening and adverse pregnancy outcome. Fetal Diagn Ther 11: 249-253. (Pubitemid 26177742)
22. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL. 1997. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet 349: 1285-1288. (Pubitemid 27192471)
23. Pihl K, Larsen T, Krebs L, Christiansen M. 2008. First trimester maternal serum PAPP-A, beta-hCG and ADAM12 in prediction of small-for-estational-age fetuses. Prenat Diagn 28: 1131-1135.
24. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. 2009. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 53: 812-818.
25. van Rijn M, van der Schouw YT, Hagenaars AM, Visser GH, Christiaens GC. 1999. Adverse obstetric outcome in low- and high-risk pregnancies: predictive value of maternal serum screening. Obstet Gynecol 94: 929-934.
26. Sibai BM, Koch MA, Freire S, et al. 2008. Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia?. Am J Obstet Gynecol 199: 268.e1-268.e9.
27. Smith GC, Shah I, White IR, Pell JP, Crossley JA, Dobbie R. 2007. Maternal and biochemical predictors of antepartum stillbirth among nulliparous women in relation to gestational age of fetal death. BJOG 114: 705-714. (Pubitemid 46788658)
28. Smith GC, Shah I, White IR, Pell JP, Crossley JA, Dobbie R. 2006. Maternal and biochemical predictors of spontaneous preterm birth among nulliparous women: a systematic analysis in relation to the degree of prematurity. Int J Epidemiol 35: 1169-1177. (Pubitemid 44605535)
29. Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. 2002. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 87: 1762-1767.
30. Spencer K, Cowans NJ, Molina F, Kagan KO, Nicolaides KH. 2008. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery. Ultrasound Obstet Gynecol 31: 147-152. (Pubitemid 351211925)
31. Summers AM, Huang T, Meier C, Wyatt PR. 2003. The implications of a false positive second-trimester serum screen for Down syndrome. Obstet Gynecol 101: 1301-1306. (Pubitemid 36694359)
32. Summers AM, Huang T, Wyatt PR. 2002. Pregnancy outcomes of women with positive serum screening results for Down syndrome and trisomy 18. Prenat Diagn 22: 269-271. (Pubitemid 34245848)
33. Toal M, Chaddha V, Windrim R, Kingdom J. 2008. Ultrasound detection of placental insufficiency in women with elevated second trimester serum alpha-fetoprotein or human chorionic gonadotropin. J Obstet Gynaecol Can 30: 198-206.
34. Wald NJ, Morris JK. 2001. Multiple marker second trimester serum screening for pre-eclampsia. J Med Screen 8: 65-68.
35. Wald NJ, Morris JK, Ibison J, Wu T, George LM. 2006. Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers. Prenat Diagn 26: 559-564. (Pubitemid 43989192)
36. Waller DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB. 1996. The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Obstet Gynecol 88: 816-822.